Introduction
Human heart and lung transplantation was first reported in 1982. ' The patients had severe pulmonary vascular disease, either primary or secondary to cardiac disease.2 3 Despite the long term problems in diagnosing rejection or infection in the transplanted lung,24 this treatment may be beneficial for patients with other lung diseases. We report our early experience of combined heart and lung transplantation in seven patients who had end stage chronic lung disease.
Methods
Between November 1982 and September 1986, 199 patients were referred for heart and lung transplantation. Of these, 53 patients were accepted on to a waiting list and 19 received a transplant. Seven of these patients had chronic lung disease. All 199 patients were severely disabled. Those who were selected for transplantation had a poor prognosis, and no further conventional treatment could be offered to them. Patients were accepted for operation if they were under 49 years of age and free of systemic illness or secondary organ dysfunction. Other contraindications were previous extensive cardiac or thoracic surgery,3 the presence ofsystemic infections, or concurrent treatment with corticosteroids. Table I gives the ages of the seven patients (range 20 to 43 years) and the diagnoses. They had been ill for from two to nine years. Two were confined to bed in hospital, and the others required frequent treatment as inpatients. As a group the maximum reported exercise tolerance was walking a distance of 100 yards (91-4 m) on the flat at their own pace (table I) . Only the patient with cystic fibrosis had infected sputum at the time ofthe operation. The organism consistently cultured from the sputum was Pseudomonas aeruginosa. The patients with cryptogenic fibrosing alveolitis, histiocytosis X, and sarcoidosis had been treated with corticosteroids and azathioprine in the past. All patients with airways obstruction were treated with inhaled bronchodilator (salbutamol) and inhaled topical steroid (beclomethasone diproprionate).
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The diagnoses of cryptogenic fibrosing alveolitis and histiocytosis X were made by open lung biopsy at the referring hospital. Sarcoidosis was diagnosed from a lymph node biopsy specimen. The diagnosis in the other patients was confirmed from histology of the lungs after transplantation.
The operation (fig 1) , selection of donors, and perioperative care have been described elsewhere.5 Immunosuppressive treatment was given with cyclosporin and prednisolone to the first patient; the other six received cyclosporin and azathioprine. Pulmonary function was recorded before and after the operation, at monthly intervals for six months, and every five months thereafter. A dry wedge spirometer was used to record forced expired volume in one second and forced vital capacity (Vitalograph, Buckingham, England). Single breath gas transfer for carbon monoxide was measured with Transfer Test equipment (P K Morgan, Chatham, Kent, England).6 Static lung volumes were recorded in a whole body plethysmograph (P K Morgan, Chatham, Kent, England).7
BRITISH MEDICAL JOURNAL VOLUME 295 1 AUGUST 1987 assisted ventilation for more than 36 hours after the operation (patient 3,) largely because of chest wall deformity, pectus carinatum, and kyphoscoliosis. Patient 7 had a recurrent chylous effusion that required continuous pleural drainage for three weeks. Patient 1 survived a severe primary cytomegalovirus infection of the small bowel that was diagnosed serologically and by culture of a gastric mucosal biopsy specimen. Patient 7 had a mild febrile illness within a week of the operation which was associated with a rise in specific IgM to cytomegalovirus but had no other disorder. His fever resolved after treatment with hyperimmune globulin. These two patients and the patient who died were seronegative for cytomegalovirus before the operation but received organs from seropositive donors. Another such patient suffered no ill effects and remained seronegative for cytomegalovirus.
Three patients (1, 2, and 5) had a bacterial bronchial infection, one at seven days, one at three months, and patient 1 had two infections at six and nine months. They all had a cough, sputum, and fever, and no radiological abnormality. The diagnosis was made by sputum culture, which showed Streptococcus pneumoniae in two and Haemophilus influenza in the other. They responded to oral amoxycillin 500 mg three times a day. During the illness small changes in forced expired volume in one second and forced vital capacity occurred, but there was little change in gas transfer for carbon monoxide or total lung capacity. A tuberculous empyema developed in patient 1, who had been treated for tuberculosis in 1971. This responded to a standard course of rifampicin, isoniazid, and ethambutol.
Patient 1 also had an episode of rejection which coincided with the start of antituberculous chemotherapy. The 
Discussion
Combined heart and lung transplantation was initially used to treat pulmonary vascular disease. Since 1984, 19 heart and lung transplants have been performed at this hospital, seven of them for chronic lung disease. Our limited experience with these seven patients indicates that with suitable selection this is a worthwhile treatment. With time lung function has returned to normal predicted values, and patients report normal exercise tolerance. In contrast to patients with pulmonary vascular disease our survivors have not developed obliterative bronchiolitis.3 8 A recent review places lung transplantation for lung disease in perspective.9 Success, however, has lagged behind that with other organs for various reasons.
Our major clinical problems have been cytomegalovirus infection and rejection. The cytomegalovirus infections were primary, occurring shortly after the operation, and are assumed to have been acquired by previously seronegative recipients from the donor.'0 This has led to a change in practice. Donors are now serotyped for cytomegalovirus, and the recipient is matched. In future it may be possible to "vaccinate" the seronegative recipients for cytomegalovirus to extend the potential range of donors.
In one patient a serious rejection episode followed the start of antituberculous treatment. As antibiotics are known to reduce the efficacy of cyclosporin" the event was expected. A full response to increased immunosuppression, including relief of symptoms, the disappearance of abnormal physical signs, and an increase in pulmonary function, was observed after 14 days of treatment.
Bacterial bronchitis occurred on three occasions but responded to treatment with conventional antibiotics, and there was no sustained loss of lung function. Three factors may have contributed to these infections: a reduction in the efficacy of the cough reflex, impaired mucociliary clearance, and interruption of the mucociliary "escalator" at the tracheal anastomosis. These patients can cough because the larynx and trachea are innervated.5 The airways below the anastomosis, however, are denervated, preventing the initiation of the cough reflex from the bronchial tree. Mucociliary clearance may also be impaired in these regions as a result of denervation,'2 1 ' although this has not yet been studied. The interruption of the mucociliary escalator at the tracheal anastomosis may also be important.
The size of the donor lungs and, the recipient's thoracic cavity must be matched. If the donor lungs are too large atelectasis and right to left shunt may occur. 4 We measure thoracic vertebral height and width of the rib cage in the chest radiograph. Three recipients, had overinflated lungs, two of whom had emphysema and one of whom had histiocytosis X. All had a normal total lung capacity after operation (96-108% of recipient values predicted by four months).
Patients with pulmonary vascular disease who undergo heart and lung transplantation have a restrictive ventilatory defect.'4 This probably reflects changes in the mobility of the chest wall after median sternotomy," which is also seen in patients after coronary artery bypass grafting and which resolves with time.'6 This effect was less obvious in our patients, in whom preoperative lung function was grossly reduced. All patients achieved a normal total lung capacity four months after the operation.
Combined heart and lung transplantation for lung disease may not be superior to transplantation of both lungs or of a single lung. 17 It is easier to transplant the heart and lungs together.4 But it is no longer thought that the transplanted heart offers a means of diagnosing rejection through an endomyocardial biopsy. ' More patients with cystic fibrosis than with other diseases are likely to benefit from combined heart and lung transplantation, particularly as most now survive until adult life.26 Selection is important; relative contraindications would be extrapulmonary disease-for example, insulin dependent diabetes mellitus, which occurs in 4% of patients, and liver disease with portal hypertension, which is present in 1%.27 It is now possible, however, to combine transplantation of the liver with transplantation of heart and lungs. Extensive pleural fibrosis from surgical treatment of recurrent pneumothorax may be an important contraindication. Recurrent pneumothorax is common in the older patients with cystic fibrosis. 28 Pulmonary infection in cystic fibrosis is not a problem since it is usually confined to the lungs. Pleural and systemic infections are rare.2' Transplantation offers the removal of the main source of sepsis. In our patient it was associated with an increase in body weight of 6 kg in the first 12 weeks. The presence of Aspergillus fumigatus is of concern as a possible opportunistic infection after transplantation. 30 We conclude that probably about 100 patients a year with lung disease in England and Wales would benefit from combined heart and lung transplantation. This should not be too great a demand on donor resources but implies that several centres need to carry out this type of surgery. There is still the problem of diagnosis and treatment of rejection.3 Transbronchial lung biopsies may help to solve this, and our experience of this technique will be reported. In addition, there remain difficulties in using cyclosporin, particularly in determining adequate treatment for the patient and avoiding nephrotoxicity.3' Nevertheless, our limited experience of heart and 313 314 BRITISH MEDICAL JOURNAL VOLUME 295 1 AUGUST 1987 lung transplantation is encouraging. This surgery offers a treatment for a wide range of end stage chronic lung disease.
